Pyridopyrimidinones

Details Pyridopyrimidinones Pyridopyrimidinones

2004-10-14

2009-06-16

Berch, Mark L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S234200, C514S264110, C544S117000, C544S279000

Reexamination Certificate

active

07547695

ABSTRACT:
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X′ have the designations cited in patent claim1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumors.

REFERENCES:
patent: 5817669 (1998-10-01), Tomita et al.
patent: 2007/0060578 (2007-03-01), Player et al.
patent: 2002/044156 (2002-06-01), None
patent: 2004/029038 (2004-04-01), None
Arora, et al., J. Pharmacol. & Experim. Therap., vol. 315, No. 3, 2005, pp. 971-979.
Hynes, Breast Cancer Res., 2000, 2, pp. 154-157.
Batchelor, et al., Cancer Cell, 11, 83-95, Jan. 2007.
Fu, et al., J. Nat. Cancer Inst., vol. 95, No. 12, Jun. 18, 2003.
Liechti et al., Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor, European Journal of Medicinal Chemistry, vol. 39, pp. 11-26, (2004).

Affiliated with

Also associated with

Rating

Pyridopyrimidinones does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridopyrimidinones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridopyrimidinones will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4106601